ArticleJournal for immunotherapy of cancer2024

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

Martin Wermke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.